Preliminary Observations and Clinical Value of N-acetyl Resonances in Ovarian Tumours Using In-vivo Proton MR Spectroscopy at 3T

Overview

Journal Eur Radiol

Specialty Radiology

Date 2011 Aug 6

PMID 21818526

Citations 2

Authors

Mayumi Takeuchi

Kenji Matsuzaki

Masafumi Harada

Affiliations

Soon will be listed here.

Abstract

Objective: To retrospectively evaluate the clinical significance of N-acetyl resonances at 2 ppm in in-vivo proton magnetic resonance (MR) spectroscopy for distinguishing mucinous and non-mucinous tumours in patients with ovarian masses.

Methods: MR spectroscopy was performed in patients with pathologically diagnosed ovarian tumours at 3T-MR imaging. Single-voxel MR spectroscopy data were collected from a single square volume of interest that encompassed the ovarian masses. The metabolite resonance peak areas at 2 ppm were quantified relative to unsuppressed water using a software package (LCModel).

Results: A total of 32 ovarian lesions in 32 patients were evaluated in this study. High metabolite peak at 2 ppm was observed in all nine mucinous tumours (9.71 +/- 7.46 mM), whereas low peak was observed in 14 of 23 non-mucinous tumours (3.12 +/- 1.42 mM) (p < 0.001). Using a cut off value of 4.45 mM for mucinous tumours had a sensitivity of 89%, specificity of 86%, PPV of 80%, and NPV of 92%.

Conclusion: Proton MR spectroscopy with quantitative evaluation of the metabolite at 2 ppm concentration, which may suggest the presence of mucinous material containing N-acetyl mucinous compounds, can provide helpful information in distinguishing mucinous and non-mucinous ovarian tumours. Key Points • MR spectroscopy helps distinguish mucinous from non-mucinous ovarian tumours. • High N-acetyl resonance at 2 ppm is observed in ovarian mucinous tumours. • Thus MR spectroscopy could improve management of these patients.

Citing Articles

Proton MR spectroscopy and the detection of malignancy in ovarian masses.

Mansour S, Gomma M, Shafik P Br J Radiol. 2019; 92(1101):20190134.

PMID: 31287729 PMC: 6732908. DOI: 10.1259/bjr.20190134.

MR imaging of ovarian masses: classification and differential diagnosis.

Foti P, Attina G, Spadola S, Caltabiano R, Farina R, Palmucci S Insights Imaging. 2015; 7(1):21-41.

PMID: 26671276 PMC: 4729709. DOI: 10.1007/s13244-015-0455-4.

References

Silverberg S . Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol. 1989; 78:85-109. DOI: 10.1007/978-3-642-74011-4_5. View

Glunde K, Jacobs M, Bhujwalla Z . Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006; 6(6):821-9. DOI: 10.1586/14737159.6.6.821. View

Jung S, Lee J, Eun Rha S, Byun J, Jung J, Hahn S . CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics. 2002; 22(6):1305-25. DOI: 10.1148/rg.226025033. View

Makar A, Baekelandt M, Trope C, Kristensen G . The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995; 56(2):175-80. DOI: 10.1006/gyno.1995.1027. View

Hess V, AHern R, Nasiri N, King D, Blake P, Barton D . Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004; 22(6):1040-4. DOI: 10.1200/JCO.2004.08.078. View

Periakaruppan A, Kesavadas C, Radhakrishnan V, Thomas B, Rao R . Unique MR spectroscopic finding in colloid-like cyst. Neuroradiology. 2007; 50(2):137-44. DOI: 10.1007/s00234-007-0324-z. View

McLean M, Priest A, Joubert I, Lomas D, Kataoka M, Earl H . Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn Reson Med. 2009; 62(4):855-61. DOI: 10.1002/mrm.22067. View

Andre E, Xu M, Yang D, Siow J, Yeo T, Xu Y . MR spectroscopy in sinus mucocele: N-acetyl mimics of brain N-acetylaspartate. AJNR Am J Neuroradiol. 2006; 27(10):2210-3. PMC: 7977234. View

Liu X, Germin B, Zhong J, Ekholm S . N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas. Magn Reson Imaging. 2010; 28(9):1390-4. DOI: 10.1016/j.mri.2010.06.015. View

10.

Lee J, Cho K, Kim Y, Kim S, Mun C, Na J . Localized in vivo 1H nuclear MR spectroscopy for evaluation of human uterine cervical carcinoma. AJR Am J Roentgenol. 1998; 170(5):1279-82. DOI: 10.2214/ajr.170.5.9574601. View

11.

Gilks C, Prat J . Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009; 40(9):1213-23. DOI: 10.1016/j.humpath.2009.04.017. View

12.

Haddadin I, McIntosh A, Meisamy S, Corum C, Styczynski Snyder A, Powell N . Metabolite quantification and high-field MRS in breast cancer. NMR Biomed. 2007; 22(1):65-76. PMC: 2628417. DOI: 10.1002/nbm.1217. View

13.

Boss E, Moolenaar S, Massuger L, Boonstra H, Engelke U, De Jong J . High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed. 2000; 13(5):297-305. DOI: 10.1002/1099-1492(200008)13:5<297::aid-nbm648>3.0.co;2-i. View

14.

Provencher S . Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14(4):260-4. DOI: 10.1002/nbm.698. View

15.

Payne G, Schmidt M, Morgan V, Giles S, Bridges J, Ind T . Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. Gynecol Oncol. 2009; 116(2):246-52. DOI: 10.1016/j.ygyno.2009.09.044. View

16.

Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T . Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging. 2001; 13(6):912-7. DOI: 10.1002/jmri.1130. View

17.

Provencher S . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993; 30(6):672-9. DOI: 10.1002/mrm.1910300604. View

18.

Hascalik S, Celik O, Sarac K, Alkan A, Mizrak B . Clinical significance of N-acetyl-L-aspartate resonance in ovarian mucinous cystadenoma. Int J Gynecol Cancer. 2006; 16(1):423-6. DOI: 10.1111/j.1525-1438.2006.00200.x. View

19.

Koyama T, Mikami Y, Saga T, Tamai K, Togashi K . Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation. Abdom Imaging. 2007; 32(6):784-95. DOI: 10.1007/s00261-007-9186-4. View

20.

Celik O, Sarac K, Hascalik S, Alkan A, Mizrak B, Yologlu S . Magnetic resonance spectroscopy features of uterine leiomyomas. Gynecol Obstet Invest. 2004; 58(4):194-201. DOI: 10.1159/000080020. View